Brokerages predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce $51.15 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $52.40 million and the lowest is $49.90 million. Eagle Pharmaceuticals reported sales of $46.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.3%. The firm is scheduled to report its next earnings report on Monday, February 25th.

On average, analysts expect that Eagle Pharmaceuticals will report full year sales of $208.40 million for the current fiscal year, with estimates ranging from $207.20 million to $209.60 million. For the next year, analysts anticipate that the business will post sales of $235.15 million, with estimates ranging from $219.80 million to $250.50 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. The business had revenue of $51.34 million for the quarter, compared to analysts’ expectations of $52.70 million. During the same period last year, the business earned $1.22 EPS. The business’s revenue was down 18.5% on a year-over-year basis.

A number of research analysts have weighed in on EGRX shares. TheStreet raised Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a report on Thursday, August 9th. Cantor Fitzgerald set a $81.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 24th. BidaskClub downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “sell” rating in a research report on Tuesday, September 18th. Finally, ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $77.17.

NASDAQ EGRX opened at $47.13 on Friday. The firm has a market cap of $702.86 million, a PE ratio of 13.99 and a beta of 1.71. Eagle Pharmaceuticals has a one year low of $46.38 and a one year high of $85.66. The company has a current ratio of 5.59, a quick ratio of 5.38 and a debt-to-equity ratio of 0.20.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $108,000. Macquarie Group Ltd. lifted its stake in shares of Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,200 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $115,000. Piedmont Investment Advisors LLC bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at $150,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at $156,000.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Further Reading: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.